Introduction: Addressing the Challenge of Resistant Cholangiocarcinoma
The landscape of biliary tract cancer treatment has been transformed by the identification of fibroblast growth factor receptor 2 (FGFR2) fusions as a primary driver in intrahepatic cholangiocarcinoma. While first-generation FGFR inhibitors like pemigatinib and futibatinib have improved outcomes, their efficacy is frequently curtailed by the emergence of secondary mutations. The clinical community has long sought therapeutic options for patients who progress on these targeted therapies. Recent findings from a Phase 2 trial of tinengotinib, published in The Lancet Gastroenterology & Hepatology, suggest that this next-generation multi-kinase inhibitor may provide a viable path forward for this difficult-to-treat population.
